# NAD+ Marketing Compliance: Why the FTC Has Your Clinic's Longevity Claims in Its Crosshairs NAD+ marketing is one of the current FTC enforcement priorities in 2026. Here's what the rules require for anti-aging, cognitive-enhancement, and longevity claims - and why most IV therapy and wellness clinic NAD+ marketing would not hold up under regulatory review. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-03-20. Reading time 10 minutes. Canonical page: https://regencompliance.ai/blog/nad-plus-marketing-compliance NAD+ marketing combines three claim categories the FTC has publicly flagged in the supplement and wellness space: anti-aging, cognitive enhancement, and longevity. NAD+ marketing concentrates all three in ways that draw regulatory attention. If you run an IV therapy clinic, wellness practice, or concierge medicine clinic offering NAD+ services, reviewing your marketing against the framework below is a useful starting point. This post walks through what NAD+ actually is (for regulatory purposes), why it’s specifically in FTC focus, the claim categories currently under enforcement, and compliant framings that preserve marketing effectiveness without triggering the specific patterns regulators target. For the FDA position on NAD+ IV administration specifically, see our companion post on [NAD+ IV therapy marketing](https://regencompliance.ai/blog/nad-iv-therapy-marketing-fda-position). Why NAD+ specifically NAD+ marketing combines three claim categories that are each independently difficult: anti-aging, cognitive enhancement, and longevity. Combining them multiplies the substantiation burden. Meanwhile, the underlying clinical evidence for many of the specific marketed outcomes is genuinely thin - which makes the gap between claim and evidence particularly visible. ## What NAD+ is, in regulatory terms NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in cellular energy metabolism and DNA repair processes. The underlying biology is genuine. The regulatory question is not about NAD+’s existence or its biological role - it’s about what specific claims about outcomes in humans are supported by adequate and reliable evidence. NAD+ products in the clinical context take several forms: - **NAD+ IV infusions.** Typically prepared as compounded formulations by licensed compounding pharmacies and administered by healthcare practices. - **NAD+ subcutaneous injections.** Lower-dose alternatives to IV administration. - **NAD+ precursor supplements (NR, NMN).**Dietary supplements marketed with structure-function claims under DSHEA. - **NAD+ precursor combined protocols.** IV combined with supplement maintenance. The marketing issues are most acute for the injectable forms (IV and SQ) because they are legally prescription preparations and the advertising falls under the prescription-drug advertising framework rather than the supplement framework. ## Why the FTC is focused on this specifically Three factors make NAD+ an enforcement priority: ### Factor 1: Aggressive consumer claims NAD+ marketing routinely makes sweeping claims - “reverses aging,” “extends lifespan,” “boosts cognition by X%,” “restores cellular function.” The claims are both specific enough to trigger substantiation requirements under the [FTC Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance) and ambitious enough to make the evidentiary gap obvious. ### Factor 2: Weak clinical evidence on outcomes The human clinical evidence for many specific marketed outcomes is thin - small studies, short durations, mixed results, limited blinding. Whatever one’s view of the underlying biology, the clinical evidence does not meet the FTC’s competent-and-reliable standard for many common claims. ### Factor 3: Vulnerable consumer target NAD+ marketing frequently targets older consumers concerned about cognitive decline, cancer patients, and patients with chronic illness. The FTC applies heightened scrutiny to marketing targeting populations that are particularly vulnerable to misleading health claims. ## The specific claim patterns under enforcement ### Pattern 1: Anti-aging reversal claims Non-compliant “Our NAD+ IV therapy reverses the aging process at the cellular level.” Compliant alternative “NAD+ is a coenzyme involved in cellular energy metabolism. Some patients report subjective improvements in energy and well-being after treatment; individual experiences vary, and research into NAD+ biology continues.” Why: 'Reverses aging' is a top-priority FTC enforcement target. Compliant framing describes what NAD+ is and what patients report without claiming biological reversal of aging. ### Pattern 2: Cognitive enhancement specifics Non-compliant “Improves memory, focus, and cognitive function - many patients report mental clarity within a single session.” Compliant alternative “Some patients describe subjective feelings of mental clarity and energy following treatment; these responses vary widely by individual and do not represent clinical evidence of cognitive enhancement.” Why: Cognitive-enhancement claims trigger both FTC substantiation rules and FDA disease-claim rules (cognitive decline is a medical diagnosis). Subjective-report framing avoids the claim while preserving the marketing message. ### Pattern 3: Longevity / lifespan extension Non-compliant “NAD+ supports longevity - studies show it may extend lifespan by up to 30%.” Compliant alternative “Research on NAD+ biology, including cellular and animal studies, continues to evolve. We do not make specific claims about lifespan extension in humans, as that level of evidence does not currently exist.” Why: Lifespan-extension claims require human clinical evidence over years or decades - which does not exist for any current NAD+ protocol. Citing cellular or animal studies to support human lifespan claims is a specific enforcement pattern. ### Pattern 4: Chronic fatigue and disease-adjacent claims Non-compliant “NAD+ therapy cures chronic fatigue syndrome and brain fog.” Compliant alternative “Some patients with fatigue or post-viral symptoms report subjective improvement with NAD+ treatment as part of a broader care plan; our medical team discusses whether this is clinically appropriate for each patient.” Why: 'Cures chronic fatigue syndrome' is a disease-treatment claim for a diagnosable medical condition. Subjective-improvement framing with provider-gated language avoids the disease claim. ### Pattern 5: Cancer-recovery or chemotherapy support Non-compliant “Our NAD+ protocol supports cancer patients through chemotherapy recovery.” Compliant alternative “[Remove entirely. Do not include this indication in public marketing without specific clinical evidence and attorney review. Cancer-related claims face the highest FTC scrutiny and the highest FDA enforcement risk.]” Why: Cancer-related marketing is the highest-risk healthcare marketing category. Even framings like 'supports' can cross into treatment claim territory. This is one of a small number of indications where the safest approach is to simply not market it. ### Pattern 6: Celebrity/testimonial-driven marketing Non-compliant “[Celebrity] swears by our NAD+ protocol - you can too!” Compliant alternative “[Remove unless documented paid endorsement with FTC-compliant material-connection disclosure in the post itself.]” Why: Celebrity implied endorsement without proper disclosure is a top-5 FTC enforcement pattern. NAD+ is a space where celebrity mentions appear frequently in clinic marketing, often without the required disclosures. The [FTC Endorsement Guides](https://www.ftc.gov/business-guidance/resources/ftcs-endorsement-guides-what-people-are-asking) - covered in our [2023 update overview](https://regencompliance.ai/blog/ftc-endorsement-guides-2023-update) - require clear-and-conspicuous material-connection disclosure for any paid or incentivized endorser relationship. ## What compliant NAD+ marketing looks like ### Lead with biology, not outcomes “NAD+ is a coenzyme present in every cell, involved in cellular energy metabolism and DNA repair processes. Research into its biology and clinical applications continues to evolve.” This is factually accurate, informative, and sets expectations without making specific outcome claims. ### Describe the service honestly “Our NAD+ infusion sessions are administered by licensed medical staff using compounded preparations from a licensed compounding pharmacy. Sessions typically take 2-4 hours depending on dose and individual tolerance.” Specific, factual, does not overclaim. ### Frame patient reports as subjective “Some patients describe subjective improvements in energy, mental clarity, or overall well-being following treatment. Individual experiences vary significantly, and these reports do not constitute clinical evidence of specific outcomes.” This captures the actual marketing message (patients often feel good) without claiming clinical effects. ### Acknowledge the evidence state “The clinical evidence for specific outcomes of NAD+ therapy in humans is still developing. We offer this service to patients interested in exploring NAD+ as part of a broader wellness approach, with a clear understanding that it is not an established treatment for any specific medical condition.” This is genuinely honest and defensibly compliant. ### Keep disease-specific indications out of public marketing Cancer, Parkinson’s, Alzheimer’s, ALS, post-viral illness, chronic fatigue syndrome, fibromyalgia - keep these out of public marketing even when clinical discussion may appropriately include them. The in-consultation conversation and the public marketing operate under different rules. The reframe that works NAD+ marketing that leads with curiosity and wellness framing (“many patients exploring cellular health,” “a wellness offering for patients interested in cellular support, metabolism, and energy”) tends to convert as well as aggressive outcome marketing - and faces far less enforcement risk. The outcome-focused marketing signals desperation; the wellness-framed marketing signals confidence. ## The supplement layer (NR, NMN) If your practice also sells NAD+ precursor supplements (NR, NMN), those operate under DSHEA - dietary supplement rules. [Structure-function claims](https://regencompliance.ai/blog/structure-function-vs-disease-claims) (“supports cellular energy”) are permitted with the required DSHEA disclaimer and adequate substantiation. Disease claims (same list: cures, treats, prevents) are not permitted in either framework. The supplement layer does not cure compliance issues in the IV or injection layer - they’re independent. ## Frequently asked questions ### Can I cite studies on NAD+ biology in my marketing? Citing studies accurately is generally fine. The issue is how the citations are used. A study on NAD+ in cells or in animals cited to support a claim about human outcomes is a substantiation mismatch - the evidence doesn’t reach the claim. Citing studies to support what you’re actually doing (“research on NAD+ biology continues”) is fine. ### What about IV drips combining NAD+ with other ingredients? Combination infusions face the same rules plus complexity from the additional ingredients. Each claim needs substantiation tied to what’s actually in the infusion. Generic “wellness boost” framing is easier to defend than specific outcome claims. ### Is NAD+ FDA-approved for anything? Nicotinamide (vitamin B3) is an approved drug for certain medical indications. NAD+ as administered in most wellness and IV therapy contexts is not FDA-approved for the marketed indications. The distinction matters for marketing language. ### What about research/clinical trial framing? Genuine clinical trials operating under an IND can discuss research purposes within the scope of the IND. A wellness clinic offering NAD+ as a service is not conducting an IND clinical trial, and framing services as research when they aren’t creates an additional misrepresentation. ### Can I show patient “before/after” energy-level testimonials? Yes, with proper FTC endorsement framing - typical- experience disclosure, material-connection disclosure if applicable, and avoidance of disease-related outcome framing. Energy and well-being testimonials are lower-risk than disease-specific testimonials because they don’t directly imply disease treatment. ### What about longevity physicians with NAD+ in their protocols? Longevity-medicine practices face the same rules, often more stringently because the entire practice is marketed around longevity outcomes. The practice-level marketing needs the same compliance treatment as the individual service-level marketing. “Longevity medicine” framing itself is increasingly drawing FTC attention when paired with specific outcome claims. Key Takeaways - NAD+ marketing is a current FTC enforcement priority - expect continued scrutiny of anti-aging, cognitive, and longevity claims. - The underlying biology is real; the specific human outcome claims typically lack the clinical evidence required for FTC substantiation. - Biology-first framing and subjective-report framing preserve marketing effectiveness while avoiding enforcement patterns. - Disease-specific indications (cancer, Alzheimer's, chronic fatigue, etc.) should stay out of public NAD+ marketing regardless of clinical appropriateness in consultation. - Compliant NAD+ marketing often converts as well as aggressive marketing - outcome-focused framing signals desperation; wellness-focused framing signals confidence. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt